Beyond Cannabis: A Comprehensive Cross-Species Guide to Cannabimimetic Plants and the Endocannabinoid System

Are Cannabinoids Exclusive to Cannabis? Understanding the Endocannabinoid System (ECS)

When most people hear the word "cannabinoids," they immediately think of Cannabis sativa. Yet across botanical and pharmacological literature, scientists frequently describe a remarkably diverse group of non-Cannabis species—ranging from endemic New Zealand liverworts and South African daisies to everyday culinary spices like black pepper, turmeric, and green tea—as having "cannabimimetic activity."

To understand how unrelated plants interact with human physiology, we first need to look at the endocannabinoid system (ECS)—an ancient homeostatic signaling network inherent to all vertebrates.

As reviewed by researchers at the University of Brescia and Karolinska Institutet in Planta (Kumar et al., 2019) and by neurologist Ethan Russo in Trends in Pharmacological Sciences (Russo, 2016), the human body continuously synthesizes its own lipid messengers "on demand" to regulate sleep, mood, nociception, immune inflammation, and gut metabolism through three core pillars:

• Two Primary Receptors (CB1R and CB2R) and Extended Channels: Type-1 cannabinoid receptors (CB1R) are densely expressed on presynaptic neurons in the central nervous system (modulating GABA and glutamate release) as well as in the gut and liver; type-2 cannabinoid receptors (CB2R) are concentrated in immune cells, the spleen, tonsils, and microglia, where they dampen inflammation without causing central psychoactivity. The ECS also cross-talks with transient receptor potential channels (TRPV1, TRPA1), GPR55, and nuclear PPAR$\gamma$ receptors.
• Two Endogenous Ligands (AEA and 2-AG): Anandamide (AEA, $N$-arachidonoylethanolamine) and 2-arachidonoylglycerol (2-AG) serve as the body's internal signaling keys.
• Two Degradative Enzymes (FAAH and MAGL): Once AEA and 2-AG complete their signaling roles, they are rapidly hydrolyzed by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively (with COX-2 also contributing to oxidative metabolism).

Non-Cannabis cannabimimetic plants do not contain illegal Cannabis narcotics; rather, they produce secondary metabolites that converse with the ECS by (1) mimicking phytocannabinoid structures, (2) selectively activating peripheral CB2 receptors, or (3) inhibiting FAAH/MAGL enzymes or cellular reuptake so the body's own AEA and 2-AG last longer.

Convergent and Parallel Evolution Across Hundreds of Millions of Years

True Cannabis belongs to the family Cannabaceae (order Rosales). Yet recent genomic and metabolomic breakthroughs prove that distant plant lineages independently evolved cannabinoid-like biosynthetic machinery from different biochemical starting points:

• Parallel Evolution in South African Woolly Umbrella (Helichrysum umbraculigerum, Asteraceae): A 2023 Nature Plants study from the Weizmann Institute of Science (Berman et al., 2023) demonstrated that Helichrysum umbraculigerum synthesizes cannabigerolic acid (CBGA) at up to 4.3% of leaf dry weight inside foliar glandular trichomes, alongside phenylethyl-side-chain amorfrutins (potent PPAR$\gamma$ modulators). Orthology analysis confirmed that its cannabinoid-forming enzymes evolved independently in parallel with Cannabis.
• Bibenzyl Cannabinoids in New Zealand and Japanese Liverworts (Radula marginata and R. perrottetii, Marchantiophyta): Bryophytes are among the oldest land plants on Earth. Studies published in Science Advances (Chicca et al., 2018) and New Phytologist (Andre et al., 2024) show that Radula liverworts bypass the fatty-acid (hexanoic acid) starter pathway used by Cannabis and instead route phenylalanine through the phenylpropanoid pathway to assemble bibenzyl cannabinoids inside cellular oil bodies:
  1. Perrottetinene ((-)-cis-PET, structural analog of THC): Crosses the blood–brain barrier and acts as a partial CB1R agonist ($\text{EC}_{50} = 406\ \text{nM}$, roughly 10-fold less potent than $\Delta^9$-trans-THC at $\text{EC}_{50} = 43\ \text{nM}$), while uniquely reducing basal brain prostaglandins ($\text{PGD}_2$ and $\text{PGE}_2$) (Chicca et al., 2018).
  2. Perrottetinene diol ((+)-trans-PTD, newly discovered natural analog of CBD): Analyzing 75 wild Radula marginata collections in New Zealand, Andre et al. (2024) isolated trans-PTD and its acid precursor PTDA from nature for the first time, revealing genetically controlled PET-dominant, PTD-dominant, and BB4G-precursor chemotypes that mirror THC, CBD, and CBG chemotypes in Cannabis.
• An Evolutionary Puzzle—Defense Without Receptors: As Kumar et al. (2019) note, plants do not express CB1 or CB2 receptors, yet ancient mosses, ferns, and liverworts produce arachidonic acid, AEA, and 2-AG, while angiosperms produce diverse terpenophenols, alkylamides, and triterpenes. Researchers hypothesize that these molecules evolved as ecological defenses against UV radiation, pathogens, and herbivores whose nervous and immune systems do express cannabinoid receptors.

Cross-Species Comparison Table: 4 Mechanisms of Cannabimimetic Plants

Synthesizing data from Kumar et al. (2019), Gertsch et al. (2008), Russo (2016), and Andre et al. (2024), we can classify cannabimimetic botanicals into four functional categories:

Functional Category & Chemical Class	Representative Plant Species	Key Marker Phytochemicals	Mechanism of Action on the ECS	Key Scientific Highlights & Cross-Links
1. Phytocannabinoid Structural Analogs (Bibenzyls / Terpenophenols)	New Zealand & Japanese Liverworts (Radula marginata, R. perrottetii)	(-)-cis-Perrottetinene (PET), (+)-trans-PTD, BB4G	cis-PET is a partial CB1R/CB2R agonist that lowers brain prostaglandins $\text{PGD}_2/\text{PGE}_2$.	2024 study confirmed 3 distinct chemotypes (PET, PTD, BB4G) analogous to THC/CBD/CBG (Andre et al., 2024).
1. Phytocannabinoid Structural Analogs (Bibenzyls / Terpenophenols)	Woolly Umbrella (Helichrysum umbraculigerum), Licorice (Glycyrrhiza spp.)	CBGA, BB4GA, Amorfrutins	Potent PPAR$\gamma$ nuclear receptor modulators with anti-inflammatory and metabolic activity.	2023 Nature Plants study proved independent parallel evolution of CBGA biosynthesis (Berman et al., 2023).
1. Phytocannabinoid Structural Analogs (Chromenes)	Rhododendrons (Rhododendron dauricum, R. ferrugineum)	Daurichromenic acid (DCA, CBC-like), Ferruginene (CBD-like)	Meroterpenoid chromene/CBD-like scaffolds with antimicrobial and antiviral properties.	Synthesized in young foliar glandular scales for plant defense (Kumar et al., 2019).
2. Selective Receptor Ligands (Sesquiterpenes / Alkylamides / Lactones)	Black Pepper (Piper nigrum), Clove, Hops, Rosemary	$(E)$-$\beta$-Caryophyllene (BCP)	Selective full CB2R agonist ($K_i = 155\ \text{nM}$) with zero affinity for central CB1R.	First proven "dietary cannabinoid" in PNAS; modulates peripheral immunity without psychoactivity (Gertsch et al., 2008).
2. Selective Receptor Ligands (Sesquiterpenes / Alkylamides / Lactones)	Coneflower (Echinacea purpurea, E. angustifolia), Maca (Lepidium meyenii)	$N$-Alkylamides	Structural mimics of endogenous AEA; bind CB2R with high affinity and modulate PPAR$\gamma$ / FAAH.	Explains the immunomodulatory pharmacology of traditional Echinacea root preparations (Kumar et al., 2019).
2. Selective Receptor Ligands (Sesquiterpenes / Alkylamides / Lactones)	Kava (Piper methysticum), Sichuan Pepper (Zanthoxylum spp.)	Yangonin, $\gamma$-Sanshool	Yangonin shows selective CB1R affinity; $\gamma$-sanshool acts as a CB1R antagonist and CB2R agonist.	Connects South Pacific kava traditions and Zanthoxylum tingling paresthesia to receptor pharmacology (Kumar et al., 2019).
3. Enzyme & Reuptake Inhibitors (Endocannabinoid Tone Enhancers)	West African & Black Pepper (Piper guineense, P. nigrum)	Guineensine, Piperine	Guineensine inhibits cellular reuptake of AEA and 2-AG; piperine activates TRPV1 channels.	Prolongs the lifespan of endogenous cannabinoids rather than acting as a direct foreign agonist (Kumar et al., 2019).
3. Enzyme & Reuptake Inhibitors (Endocannabinoid Tone Enhancers)	Bursera / Protium Resins, Lotus (Nelumbo nucifera)	$\alpha,\beta$-Amyrin, Euphol	Inhibits MAGL enzyme, slowing the hydrolysis of endogenous 2-AG.	Widespread pentacyclic triterpenes that indirectly elevate peripheral and central 2-AG tone (Kumar et al., 2019).
3. Enzyme & Reuptake Inhibitors (Endocannabinoid Tone Enhancers)	Tea (Camellia sinensis), Magnolia Bark (Magnolia officinalis), Red Clover / Soy, Flavonoid-Rich Herbs (Ilex, Rubus idaeus)	Catechins, Magnolol / Honokiol, Biochanin A, Kaempferol, Quercetin	Kaempferol and Biochanin A inhibit FAAH (preserving AEA); magnolol is a partial CB2R agonist; catechins show mild CB1R/CB2R affinity.	Everyday teas, berries, and Ilex infusions gently support ECS enzyme balance (Kumar et al., 2019).
4. Non-ECS Counter-Example ("False Marijuana" Vernacular)	Zornia latifolia (colloquially "Maconha brava")	Syzalterin + Genistein (1:9 phytocomplex)	Contains zero cannabinoids or alkaloids; inhibits cortical neuron firing via flavonoid synergy.	Proves that a cannabis-like folk name does not mean a plant contains cannabinoids (see Article 1-2).

Why Distinguishing CB1 Agonists, Selective CB2 Agonists, and Enzyme Inhibitors Matters

Grouping these plants under the umbrella term "cannabimimetic" does not mean they produce identical physiological effects:

• Direct Central CB1R Agonism (e.g., $\Delta^9$-THC and Radula cis-PET): Because CB1 receptors are abundant in the cerebral cortex and hippocampus, strong CB1R activation alters neurotransmitter release and induces the classic rodent "tetrad" (analgesia, hypothermia, catalepsy, and hypolocomotion). Even here, Radula cis-PET is roughly 10 times less potent than THC at CB1R and suppresses brain prostaglandins (Chicca et al., 2018).
• Selective Peripheral CB2R or PPAR$\gamma$ Activation (e.g., $\beta$-Caryophyllene, Echinacea Alkylamides, Magnolol): Because CB2 receptors reside primarily on immune cells and peripheral tissues, selective CB2R ligands produce zero intoxication or psychoactivity, focusing instead on inflammatory cytokine modulation (Gertsch et al., 2008; Kumar et al., 2019).
• Gentle FAAH / MAGL or Reuptake Inhibition (e.g., Kaempferol, Biochanin A, $\beta$-Amyrin, Guineensine): Rather than forcing receptors open, enzyme and uptake inhibitors slow the breakdown of the body's own on-demand AEA and 2-AG, offering subtle, physiologically bounded modulation.

Evidence Boundaries, Conservation Ethics, and Practical Herbal Selection

• Separate In Vitro Receptor Affinity from Human Clinical Claims: Many polyphenols and triterpenes reviewed by Kumar et al. (2019) (such as catechins, anthocyanins, and quercetin) exhibit micromolar receptor binding or enzyme inhibition in vitro, which cannot be directly equated to clinical drug efficacy from drinking a cup of herbal tea.
• Do Not Confuse Folk Names with Cannabinoid Content: As demonstrated in Article 1-2 on Zornia latifolia, Brazilian "Maconha brava" contains no cannabinoids at all, acting instead via the rare flavone syzalterin and genistein (Alloisio et al., 2020).
• Respect Indigenous Guardianship and Conservation of Rare Species: Andre et al. (2024) emphasize that New Zealand's endemic liverwort Radula marginata (Māori: Wairuakohu) grows extremely slowly (~1 mm per month), is classified as At Risk–Declining, and is a culturally treasured taonga under Māori guardianship (kaitiaki). Ethical research focuses on axenic tissue culture or heterologous biosynthesis rather than wild harvesting.
• Appreciate Everyday Legal Botanicals for Their True Phytochemical Diversity: Understanding the ECS helps us appreciate how everyday legal herbs—from $\beta$-caryophyllene-rich spices to kaempferol- and catechin-rich teas—participate in a broad evolutionary dialogue between plants and human physiology.

Frequently Asked Questions (FAQ)

Q1: What are "cannabimimetic plants," and do they contain illegal cannabis compounds?

Cannabimimetic plants are non-Cannabis botanicals that contain zero $\Delta^9$-THC, yet synthesize secondary metabolites (terpenes, polyphenols, alkylamides, or bibenzyls) capable of modulating the human endocannabinoid system (ECS) directly via CB1/CB2 receptors or indirectly via FAAH/MAGL enzymes (Kumar et al., 2019). Common examples include black pepper, Echinacea, green tea, turmeric, and magnolia bark.

Q2: Why is $\beta$-caryophyllene in black pepper called a "dietary cannabinoid"?

In a landmark PNAS study (Gertsch et al., 2008), $(E)$-$\beta$-caryophyllene—abundant in black pepper, clove, rosemary, and hops essential oils—was shown to selectively bind and activate peripheral CB2 receptors ($K_i = 155\ \text{nM}$) without binding central CB1 receptors, making it a non-psychoactive dietary CB2 agonist.

Q3: How do the cannabinoids in Radula marginata liverwort differ from those in Cannabis?

Radula marginata synthesizes bibenzyl cannabinoids with a phenylethyl tail via the phenylpropanoid pathway, including perrottetinene (cis-PET, analogous to THC) and perrottetinene diol (trans-PTD, discovered in nature in 2024 as an analog of CBD) (Andre et al., 2024). cis-PET is roughly 10 times less potent than THC at CB1R and uniquely reduces brain prostaglandins $\text{PGD}_2$ and $\text{PGE}_2$ (Chicca et al., 2018).

Q4: How do flavonoids in herbal teas (such as kaempferol and catechins) interact with the ECS?

Rather than strongly activating CB1 receptors, dietary flavonoids such as kaempferol (found in Ilex, tea, and many herbs) and biochanin A inhibit fatty acid amide hydrolase (FAAH), slowing the breakdown of the body's own anandamide (AEA) (Kumar et al., 2019).

References & Primary Sources

1. Kumar, A., Premoli, M., Aria, F., Bonini, S. A., Maccarinelli, G., Gianoncelli, A., Memo, M., & Mastinu, A. (2019). Cannabimimetic plants: are they new cannabinoidergic modulators? Planta, 249(6), 1681–1694. DOI: 10.1007/s00425-019-03138-x (PubMed )
2. Andre, C. M., Sansom, C. E., Plunkett, B. J., Hamiaux, C., Massey, L., Chan, A., Caddie, M., Espley, R. V., & Perry, N. B. (2024). Unique bibenzyl cannabinoids in the liverwort Radula marginata: parallels with Cannabis chemistry. New Phytologist, 246(6), 2666–2682. DOI: 10.1111/nph.20349 (PubMed | PMC Full Text )
3. Berman, P., de Haro, L. A., Jozwiak, A., Panda, S., Pinkas, Z., Dong, Y., Cveticanin, J., Barbole, R., Livne, R., Scherf, T., et al. (2023). Parallel evolution of cannabinoid biosynthesis. Nature Plants, 9(5), 817–831. DOI: 10.1038/s41477-023-01402-x (PubMed)
4. Chicca, A., Schafroth, M. A., Reynoso-Moreno, I., Erni, R., Petrucci, V., Carreira, E. M., & Gertsch, J. (2018). Uncovering the psychoactivity of a cannabinoid from liverworts associated with a legal high. Science Advances, 4(10), eaat2166. DOI: 10.1126/sciadv.aat2166 (PubMed | PMC Full Text)
5. Gertsch, J., Leonti, M., Raduner, S., Racz, I., Chen, J.-Z., Xie, X.-Q., Altmann, K.-H., Karsak, M., & Zimmer, A. (2008). Beta-caryophyllene is a dietary cannabinoid. Proceedings of the National Academy of Sciences (PNAS), 105(26), 9099–9104. DOI: 10.1073/pnas.0803601105 (PubMed | PMC Full Text)
6. Russo, E. B. (2016). Beyond Cannabis: Plants and the Endocannabinoid System. Trends in Pharmacological Sciences, 37(7), 594–605. DOI: 10.1016/j.tips.2016.04.005 (PubMed)
7. Alloisio, S., Clericuzio, M., Nobile, M., Salis, A., Damonte, G., Canali, C., Fortuna-Perez, A. P., Cornara, L., & Burlando, B. (2020). Cannabis-like activity of Zornia latifolia Sm. detected in vitro on rat cortical neurons: major role of the flavone syzalterin. Drug and Chemical Toxicology, 45(3), 1169–1180. DOI: 10.1080/01480545.2020.1788057 (PubMed )